¼¼°èÀÇ È¯ÀÚ Ç÷¾× °ü¸®(PBM) ½ÃÀå : Á¦Ç°º°, ÄÄÆ÷³ÍÆ®º°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Patient Blood Management Market, By Product, By Component, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1756482
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 365 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,482,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,413,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,792,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 154¾ï 7,898¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³â¿¡ °ÉÃÄ CAGR 7.98%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå - ½ÃÀå ¿ªÇÐ

ºóÇ÷ ¹× ¸¸¼º ÁúȯÀÇ Áõ°¡

½ÉÇ÷°ü Áúȯ, ¾Ï, ½ÅÀå Áúȯ µî ºóÇ÷ ¹× ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ´Â °ÍÀº ȯÀÚ Ç÷¾× °ü¸®(PBM) ½ÃÀåÀÇ ¼ºÀå¿¡ ÁÖ¿äÇÑ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº Á¾Á¾ »ó´çÇÑ ÃâÇ÷À̳ª ÀûÇ÷±¸ »ý¼º °¨¼Ò¸¦ ÃÊ·¡ÇÏ¿© º¸´Ù È¿°úÀûÀÎ Ç÷¾× °ü¸® Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù. Àü ¼¼°è Àα¸°¡ °í·ÉÈ­µÇ°í ÀÌ·¯ÇÑ ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀº Ç÷¾× »ç¿ëÀ» ÃÖÀûÈ­ÇÏ°í ¼öÇ÷ÀÇ Çʿ伺À» ÁÙÀ̸ç ȯÀÚÀÇ Ä¡·á °á°ú¸¦ °³¼±Çϱâ À§ÇØ PBMÀ¸·Î ´«À» µ¹¸®°í ÀÖ½À´Ï´Ù. PBM Àü·«Àº ¸ÂÃãÇü Ä¡·á ¹× ÁßÀ縦 ÅëÇØ ºóÇ÷À» °ü¸®ÇÏ¿© ¼öÇ÷°ú °ü·ÃµÈ À§ÇèÀ» ÁÙÀ̰í ȸº¹À» ÃËÁøÇÕ´Ï´Ù. °á°úÀûÀ¸·Î ¸¸¼º ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÃâÇ÷À» ÃÖ¼ÒÈ­Çϰí ÀûÇ÷±¸ »ý¼ºÀ» °³¼±Çϸç ÀüÅëÀûÀÎ ¼öÇ÷ÀÇ ´ë¾ÈÀ» Á¦°øÇÏ´Â PBM ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀº ½ÃÀå È®Àå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

ȯÀÚÀÇ Ç÷¾× °ü¸® ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®¿¡ µû¸£¸é ¼¼°èÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº 2024-2032³â¿¡ °ÉÃÄ ¾à 7.98%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

2024³â Á¦Ç°º° ºÎ¹®¿¡¼­´Â ÀåÄ¡ ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î 2024³â¿¡´Â º´¿øÀÌ °¡Àå ¸¹Àº ¼öÀÔÀ» âÃâÇß½À´Ï´Ù.

Áö¿ªº°·Î´Â 2024³â ºÏ¹Ì°¡ °¡Àå ¼öÀÍÀ» ¿Ã¸° Áö¿ªÀ̾ú½À´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®

¼¼°èÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº Á¦Ç°, ÄÄÆ÷³ÍÆ®, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªÀÇ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸®(PBM) ½ÃÀåÀº ±â±â, ºÎ¼Óǰ, ½Ã¾à ¹× ŰƮ, ¼ÒÇÁÆ®¿þ¾î µî ³× °¡Áö ÁÖ¿ä Á¦Ç° ºÎ¹®À¸·Î ³ª´¹´Ï´Ù. ÀÌ Áß ±â±â°¡ ½ÃÀåÀ» Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â Ç÷¾× °ü·Ã »óŸ¦ ¸ð´ÏÅ͸µ ¹× °ü¸®ÇÏ´Â µ¥ »ç¿ëµÇ´Â Ç÷¾× ¼öÁý ½Ã½ºÅÛ, Ç÷¾× ó¸® ÀåÄ¡ ¹× Áø´Ü ±â±â¿Í °°Àº ÀåÄ¡°¡ Æ÷ÇԵ˴ϴÙ. ±â±â°¡ ½ÃÀåÀ» Áö¹èÇÏ´Â ÀÌÀ¯´Â Á¤È®ÇÑ Ç÷¾× ºÐ¼®À» °¡´ÉÇÏ°Ô Çϰí, ÃâÇ÷À» ÁÙÀ̸ç, ÀÓ»ó ȯ°æ¿¡¼­ ¼öÇ÷ °üÇàÀ» °³¼±ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®ÀÔ´Ï´Ù. PBMÀº ÃâÇ÷À» ÃÖ¼ÒÈ­Çϰí Ç÷¾× »ç¿ëÀ» ÃÖÀûÈ­ÇÏ´Â °ÍÀ» °­Á¶Çϱ⠶§¹®¿¡ ±â±â´Â ÀÌ·¯ÇÑ ¸ñÇ¥ ´Þ¼º¿¡ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ ÀÇ·á ±â¼úÀÇ ¹ßÀü°ú Ç÷¾× Àý¾àÇü ¼ö¼ú ±â¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çõ½ÅÀûÀÌ°í °í¼º´ÉÀÇ ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¼ö¼ú ¹× ÁßȯÀÚ Ä¡·á¿¡¼­ Á¤È®ÇÑ Ç÷¾× °ü¸®ÀÇ Á߿伺ÀÌ Ä¿Áö°í ÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±â±â´Â PBM ½ÃÀå¿¡¼­ ¼±µµÀûÀÎ Á¦Ç° ºÎ¹®À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î ½ÃÀåÀº Ç÷¾× ÀºÇà, º´¿ø ¹× Áø´Ü Ŭ¸®´Ð, º´¸®ÇÐ ¿¬±¸¼Ò·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áß º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» Áö¹èÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. º´¿øÀº PBM °üÇàÀÌ °¡Àå ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÇ´Â 1Â÷ ÀÇ·á ½Ã¼³·Î, ƯÈ÷ ¼ö¼ú, ¿Ü»ó Ä¡·á ¹× ÁßȯÀÚ °ü¸®¿¡ ¸¹ÀÌ »ç¿ëµË´Ï´Ù. ¼öÇ÷, ¼ö¼ú ¹× ȯÀÚ ÀÔ¿ø °Ç¼ö°¡ ¸¹Àº º´¿øÀº ÃâÇ÷À» °ü¸®Çϰí, Ç÷¾× »ç¿ëÀ» ÃÖÀûÈ­Çϸç, ¼öÇ÷ °ü·Ã À§ÇèÀ» ÁÙÀ̱â À§ÇØ Á¾ÇÕÀûÀÎ PBM ½Ã½ºÅÛÀÌ ÇÊ¿äÇÕ´Ï´Ù. º´¿ø¿¡¼­ PBMÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ´Â °ÍÀº º¹ÀâÇÑ ¼ö¼úÀÇ Áõ°¡, ¸¸¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡, ȯÀÚ Ä¡·á °á°ú °³¼±¿¡ ´ëÇÑ °­Á¶¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´¿øÀº Ç÷¾× °ü¸®¿¡ °í±Þ ±â¼úÀ» µµÀÔÇÏ´Â °æ¿ì°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â PBM ½ÇõÀÇ È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Ç÷¾× ÀºÇà°ú Áø´Ü Ŭ¸®´Ðµµ PBM¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏÁö¸¸, ȯÀÚ Ä¡·á¿Í Ä¡·á¿¡ Á÷Á¢ °ü¿©Çϱ⠶§¹®¿¡ º´¿øÀº ¿©ÀüÈ÷ ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ·Î ³²¾Æ ÀÖ½À´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î, ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº ºÏ¹Ì, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ ¾Æ¸Þ¸®Ä«, À¯·´, Áßµ¿, ¾ÆÇÁ¸®Ä« Áö¿ª¿¡ °ÉÃÄ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªµéÀº »ç¾÷À» À¯Ä¡ÇÏ´Â ±¹°¡¿¡ µû¶ó ´õ ¼¼ºÐÈ­µË´Ï´Ù.

ºÏ¹Ì´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶ó¿Í º´¿ø ¹× ÀÇ·á ½Ã¼³¿¡¼­ PBM °üÇàÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ȯÀÚ Ç÷¾× °ü¸®(PBM) ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ Áö¿ªÀÔ´Ï´Ù. ¹Ì±¹Àº ÀÇ·á ½Ã½ºÅÛÀÌ PBM ¼Ö·ç¼ÇÀ» ÅëÇØ ¼öÇ÷ °ü·Ã ÇÕº´ÁõÀ» ÁÙÀ̰í ȯÀÚ °á°ú¸¦ ÃÖÀûÈ­ÇÏ´Â µ¥ Á¡Á¡ ´õ ÁýÁßÇϰí ÀÖ´Â ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. FDA¿Í °°Àº ±â°üÀÇ ±ÔÁ¦ Áö¿ø°ú PBMÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó PBMÀÇ Ã¤ÅÃÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ½ÃÀå Âü¿©ÀÚÀÇ Á¸Àç¿Í Ç÷¾× °ü¸® ±â±âÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀÌ ºÏ¹ÌÀÇ ½ÃÀå ¸®´õ½Ê¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ °­·ÂÇÑ ÀÇ·áºñ ÁöÃâ°ú º¹ÀâÇÑ ÀÇ·á Ä¡·á¸¦ ÇÊ¿ä·Î ÇÏ´Â °í·ÉÈ­ Àα¸´Â PBM ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

À¯·´Àº PBM ½ÃÀå¿¡¼­ ¶Ç ´Ù¸¥ ÁÖ¿ä Áö¿ªÀ¸·Î, °­·ÂÇÑ ÀÇ·á ½Ã½ºÅÛ, °í·ÉÈ­ Àα¸, Ç÷¾× ¼Õ½Ç ¹× ¼öÇ÷ ÃÖ¼ÒÈ­¿¡ ´ëÇÑ °­Á¶°¡ ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º µî À¯·´ ±¹°¡µéÀÌ ½ÃÀåÀ» ÁÖµµÇϸç, ÀÇ·á Á¦°øÀÚµéÀº ȯÀÚ ¾ÈÀü °­È­¿Í ÀÇ·á ºñ¿ë Àý°¨À» À§ÇØ PBM ½ÇõÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. À¯·´ ¿¬ÇÕÀÇ ÀÇ·á Á¤Ã¥Àº ƯÈ÷ º´¿ø°ú ¼ö¼ú ¼¾ÅÍ¿¡¼­ PBM Àü·« äÅÃÀ» Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ, Ç÷¾× Àý¾àÇü ¼ö¼ú ±â±¸ ¹× Áø´Ü µµ±¸¿Í °°Àº ÀÇ·á ±â¼úÀÇ ¹ßÀüµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. À¯·´ÀÇ Áøº¸ÀûÀÎ ÀÇ·á ¹× È¯ÀÚ Ä¡·á Á¢±Ù ¹æ½ÄÀº ÀÌ Áö¿ª¿¡¼­ PBM ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ º¸ÀåÇÕ´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå - °æÀï ±¸µµ

ȯÀÚ Ç÷¾× °ü¸®(PBM) ½ÃÀåÀÇ °æÀï ¿ªÇÐÀº ±âÁ¸ ¾÷ü¿Í ½ÅÈï Çõ½Å ±â¾÷¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Immucor, Inc. µî ÁÖ¿ä ±â¾÷µéÀº ¾ÈÀü¼º, È¿À²¼º, ±ÔÁ¦ ±âÁØ Áؼö µîÀ» ÁßÁ¡À¸·Î ÇÑ ´Ù¾çÇÑ °í±Þ PBM ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¸ç ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº Ç÷¾× °ü¸® ½Ã½ºÅÛ °³¼±°ú ¼öÇ÷ ÇÁ·ÎÅäÄÝ °­È­¿¡ ¿¬±¸ °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î ±â¾÷µéµµ °í±Þ Áø´Ü µµ±¸¿Í Ç÷¾× Àý¾àÇü ¼ö¼ú µµ±¸ µî Çõ½ÅÀûÀÎ ±â¼úÀ» ¹ÙÅÁÀ¸·Î ½ÃÀå¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷ °£ÀÇ °æÀïÀº Áö¼ÓÀûÀÎ Á¦Ç° Çõ½ÅÀ» ÃËÁøÇÏ°í °íǰÁú PBM ¼Ö·ç¼ÇÀÇ ¾ÈÁ¤ÀûÀÎ °ø±ÞÀ» º¸ÀåÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, F. Hoffmann-La Roche Ltd.¿Í Grifols, S.A.´Â Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ Àû±ØÀûÀ¸·Î È®ÀåÇϰí ÀÖÀ¸¸ç, B. Braun Melsungen AG¿Í Bio-Rad Laboratories, Inc.´Â Àü·«Àû ÀμöÇÕº´°ú Çù·ÂÀ» ÅëÇØ ½ÃÀå ÁöÀ§¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ȯÀÚ Ç÷¾× °ü¸®ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ȯÀÚ Ç÷¾× °ü¸® »ê¾÷ ¿¬±¸

Á¦5Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå »óȲ

Á¦7Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå : Á¦Ç°º°

Á¦8Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå : ¼ººÐº°

Á¦9Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå - ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå : Áö¿ª

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ȯÀÚ Ç÷¾× °ü¸® »ê¾÷

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Patient Blood Management Market size was valued at USD 15,478.98 Million in 2024, expanding at a CAGR of 7.98% from 2024 to 2032.

Patient Blood Management (PBM) is a comprehensive, evidence-based approach aimed at optimizing the care of patients who may require blood transfusions. It focuses on minimizing the need for transfusions by utilizing various strategies such as improving the patient's own blood volume and quality before, during, and after medical procedures. PBM includes three main pillars: optimization of erythropoiesis (promoting the body's natural production of red blood cells), minimization of blood loss (reducing surgical and diagnostic blood loss), and patient-centered transfusion strategies (ensuring transfusions are given only when absolutely necessary). The goal of PBM is to enhance patient outcomes by improving the management of anemia, reducing the risks associated with transfusions, and promoting the use of alternatives. This approach is particularly beneficial in surgical settings, trauma care, and chronic conditions where blood management plays a vital role in recovery and overall health.

Patient Blood Management Market- Market Dynamics

Rising Prevalence of Anemia and Chronic Diseases

The increasing prevalence of anemia and chronic diseases, such as cardiovascular disorders, cancer, and kidney disease, is a major driver for the growth of the Patient Blood Management (PBM) market. These conditions often lead to significant blood loss or decreased red blood cell production, necessitating more effective blood management strategies. As the global population ages and the incidence of these diseases rises, healthcare providers are turning to PBM to optimize blood use, reduce the need for transfusions, and improve patient outcomes. PBM strategies help manage anemia through tailored therapies and interventions, reducing the risks associated with transfusions and enhancing recovery. Consequently, the growing burden of chronic diseases is driving demand for PBM solutions that focus on minimizing blood loss, improving erythropoiesis, and offering alternatives to traditional transfusions. This trend significantly impacts the market's expansion.

PATIENT BLOOD MANAGEMENT Market- Key Insights

According to our research analyst, the global Patient Blood Management Market is expected to develop at a CAGR of approximately 7.98% between 2024-2032.

Segmented by Product in 2024, the Instruments category dominated the market.

Based on End User segmentation, the Hospitals generated the most income in 2024.

Based on region, in 2024, North America was the region with the highest revenue.

Patient Blood Management Market- Segmentation Analysis:

The global Patient Blood Management market is divided into three categories: product, component, end user and region.

The Patient Blood Management (PBM) market is segmented into four key product categories: Instruments, Accessories, Reagents and Kits, and Software. Among these, Instruments are expected to dominate the market. This segment includes devices such as blood collection systems, blood processing equipment, and diagnostic instruments used to monitor and manage blood-related conditions. The dominance of instruments is attributed to their critical role in enabling accurate blood analysis, reducing blood loss, and enhancing transfusion practices in clinical settings. As PBM emphasizes minimizing blood loss and optimizing blood use, instruments are central to these objectives. Additionally, advancements in medical technologies and the growing adoption of blood-saving surgical techniques drive the demand for innovative, high-performance instruments. The importance of precise blood management in surgeries and critical care, coupled with increasing healthcare investments, positions instruments as the leading product category within the PBM market.

By End User the market is segmented into Blood Banks, Hospitals and Diagnostic Clinics and & Pathology Labs. Among these, the Hospitals segment is set to dominate. Hospitals are the primary healthcare settings where PBM practices are most extensively applied, particularly in surgical procedures, trauma care, and critical patient management. With the high volume of blood transfusions, surgeries, and patient admissions, hospitals require comprehensive PBM systems to manage blood loss, optimize blood use, and reduce transfusion-related risks. The growing adoption of PBM in hospitals is driven by the increasing number of complex surgeries, the rising incidence of chronic diseases, and the emphasis on improving patient outcomes. Additionally, hospitals are increasingly implementing advanced technologies for blood management, contributing to the expansion of PBM practices. While blood banks and diagnostic clinics also play essential roles in PBM, hospitals remain the dominant end user due to their direct involvement in patient care and treatment.

Patient Blood Management Market- Geographical Insights

Geographically, the Patient Blood Management Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America is a dominant region in the Patient Blood Management (PBM) market, driven by the advanced healthcare infrastructure and the growing adoption of PBM practices in hospitals and healthcare facilities. The U.S. leads the market, where healthcare systems are increasingly focusing on reducing transfusion-related complications and optimizing patient outcomes through PBM solutions. Regulatory support from agencies like the FDA, along with rising awareness about the benefits of PBM, further fuels its adoption. Additionally, the presence of key market players and continuous technological advancements in blood management instruments contribute to North America's market leadership. The region's robust healthcare spending and an aging population requiring complex medical treatments further drive the demand for PBM solutions.

Europe is another key region in the PBM market, with significant growth attributed to a strong healthcare system, an aging population, and an increasing emphasis on minimizing blood loss and transfusions. Countries such as Germany, the U.K., and France lead the European market, with healthcare providers increasingly adopting PBM practices to enhance patient safety and reduce healthcare costs. The European Union's healthcare policies support the adoption of PBM strategies, particularly in hospitals and surgical centers. In addition, advancements in medical technology, such as blood-saving surgical instruments and diagnostic tools, play a pivotal role in driving market growth. Europe's progressive approach to healthcare and patient care ensures continued demand for PBM solutions in the region.

Patient Blood Management Market- Competitive Landscape:

The competitive dynamics of the Patient Blood Management (PBM) market are shaped by both established players and emerging innovators. Major companies like Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, and Immucor, Inc. lead the market, offering a range of advanced PBM solutions that prioritize safety, efficiency, and compliance with regulatory standards. These companies focus heavily on research and development to improve blood management systems and enhance transfusion protocols. New players are also entering the market with innovative technologies, such as advanced diagnostic tools and blood-saving surgical instruments. The competition among these companies encourages continuous product advancements and ensures a steady supply of high-quality PBM solutions. For instance, F. Hoffmann-La Roche Ltd. and Grifols, S.A. have been actively expanding their product portfolios, while B. Braun Melsungen AG and Bio-Rad Laboratories, Inc. continue to strengthen their positions through strategic acquisitions and collaborations.

Recent Developments:

In 2023, Grifols acquired 25 plasma donation centers in the U.S. from BPL Plasma Inc., enhancing its capacity by approximately 1 million liters annually. This strategic move strengthens Grifols' global leadership in plasma collection, supporting the growing demand for plasma-derived therapies. The acquisition aligns with Grifols' commitment to increasing patient access to life-saving treatments.

In October 2024, Terumo Blood and Cell Technologies introduced the Reveos(TM) Automated Blood Processing System in the U.S., in collaboration with Blood Centers of America. This innovative system automates the separation of whole blood into its components platelets, plasma, and red blood cells streamlining the process and improving efficiency. Reveos aims to enhance blood center operations and meet the increasing demand for blood products.

In August 2022, Abbott Laboratories launched a new blood testing platform designed to improve the accuracy and speed of diagnostics in patient blood management. This advanced platform supports healthcare providers in making timely and informed decisions, optimizing patient outcomes, and reducing the need for unnecessary transfusions. Abbott's innovation underscores its commitment to advancing PBM practices.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PATIENT BLOOD MANAGEMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT - MARKET ANALYSIS, 2019 - 2032

GLOBAL PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT- MARKET ANALYSIS, 2019 - 2032

GLOBAL PATIENT BLOOD MANAGEMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL PATIENT BLOOD MANAGEMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Patient Blood Management Market Overview

2. Executive Summary

3. Patient Blood Management Key Market Trends

4. Patient Blood Management Industry Study

5. Patient Blood Management Market: COVID-19 Impact Analysis

6. Patient Blood Management Market Landscape

7. Patient Blood Management Market - By Product

8. Patient Blood Management Market - By Component

9. Patient Blood Management Market - By End User

10. Patient Blood Management Market- By Geography

11. Key Vendor Analysis- Patient Blood Management Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â